Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
Is Hims & Hers Health Stock a Buy?
Hims & Hers has carved a strong niche in the men's healthcare segment while expanding into other areas. The weight-loss category is a huge opportunity for the company.
Why Hims & Hers Stock Crashed on Tuesday
Eli Lilly's Zepbound got a 50% price cut that could take some of Hims & Hers growth potential. Lower-cost drugs could be good news for Hims & Hers long term.
Eli Lilly Is Offering a Cheaper Form of Zepbound. What It Means for Hims & Hers Stock.
The new option is priced at a 50% or more discount compared to other weight-loss drugs.
What Is Going On With Hims & Hers Stock?
After a strong start to the year, the stock is down 30% since June.
Hims & Hers Health: Healthy Gift
Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.
Hims & Hers: Great Value Amid Unwarranted Concerns (Rating Upgrade)
Hims & Hers stock has dropped ~30% from recent peaks despite raising its outlook for FY24. Investors are concerned over projections for the company's weight loss compound drugs, especially if the FDA-approved Wegovy and Ozempic see better supply. Still, the company's weight loss revenue is only contributing a small fraction of its outstanding growth rates today, built across a wide range of specialties.
Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Subscriber growth reaccelerated, focus on personalized products, over 40% subscribers use personalized solutions. Stock-based compensation concern, $100M buyback program, increased marketing spend, positive outlook for Hims' future. GLP-1 offering still in a gray area, path forward looks difficult but possible.
